British gene therapy developer Orchard Therapeutics will go IPO on Nasdaq, according to SEC filings. The company plans to raise $172.5m as ADS in an IPO underwritten by J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow to balance its costs, which rose from US$13m to US$138m this year. Financial markets are expected to react positively.
Diagnostics company sphingotec GmbH successfully closed a 20m growth equity financing round led by international specialist investors HBM Healthcare Investments, HBM BioCapital II LP (HBM) and Wellington Partners.
Researchers at at VHIO in Barcelona, Spain, and Roche in Schlieren have presented a bi-specific antibody that prevents the side effects of HER2-targeting compounds.
Life Sciences venture capitalist Forbion has closed its new flagship fund, Forbion IV, at 360m, 90m above its original target of 250m.
Matured, diversified and willing to expand this is how the Spanish biotech sector presented itself during BIOSPAIN 2018 in Seville. Andalusia has launched the first bioeconomy policy strategy in Spain.
Barcelona-based Minoryx Therapeutics announced during BIOSPAIN 2018 it has raised another 21.3m in a Series B financing bringing its assets to a total of 50M.
A team of researchers from the US and the UK have found that CD4-positive T cells harboring the PD-1 immune checkpoint protein can promote excessive connective tissue formation in lung cells.
A new gene drive can cause the complete collapse of caged malaria-carrying mosquito populations, researchers from Imperial College report in Nature Biotechnology.
